While the economic downturn took a toll on most markets, the US contract research organization (CRO) market bucked the trend to post impressive growth rates of 8.5 per cent in 2009. The slowdown in funding for early-stage projects has, no doubt, dampened the market’s prospects for the next three years to four years, but this lack of funding has also restricted companies from investing in in-house clinical trials, creating opportunities for CROs.
Merck & Co. is close to settling patent lawsuits against Teva Pharmaceutical Industries Ltd. (TEVA) over a generic version of the cholesterol drug Vytorin, according to a federal court document.
Albany Molecular Research (AMRI) posted a modest net loss on costs and restructuring charges, but saw revenue grow considerably in the first quarter thanks to contracting business and royalties.
INC Research has entered a definitive merger agreement to acquire Kendle International for approximately $232 million in cash. Kendle is a top global CRO with Phase I-IV clinical development expertise and more than 3,000 associates in 31 countries.
GlaxoSmithKline Plc (GSK), after setting aside more than $6 billion to help settle lawsuits over medicines including its Avandia diabetes drug, is poised to resolve 1,000 more cases, a lawyer for patients said.
Researchers at the University of Utah went looking for XMRV in patients with chronic fatigue syndrome and came up empty-handed.